Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Human immunoglobulin is a sterile solution made from human plasma. Diseases such as primary immunodeficiency are treated by administering human immunoglobulin through intravenous injection (IGIV). Human immunoglobulin also helps in increasing the platelets (blood clotting cells) in people with immune thrombocytopenic purpura and prevents infections in people with B-cell chronic lymphocytic leukemia. Patients of Kawasaki syndrome are administered human immunoglobulin to prevent aneurysm caused due to weakening of the main artery in the heart.

Furthermore, intravenous human immunoglobulin (pH4) is being extensively researched in order to develop a treatment of COVID-19. This is likely to drive demand of human immunoglobulin (pH4) for intravenous injection and boost the growth of the global human immunoglobulin (ph4) for intravenous injection (COVID-19) market during the forecast period. 

The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market is estimated to be valued at US$ 43,205.84 million in 2020 and is expected to exhibit a CAGR of 12.7% during the forecast period (2020-2027).

Figure 1. Global Human Immunoglobulin (ph4) for Intravenous Injection (COVID-19) Market Value (US$ Mn), by Region, 2020

Human Immunoglobulin (pH4) for Intravenous Injection  | Coherent Market Insights

The increasing incidence of disease outbreaks is expected to propel the market growth during the forecast period

The increasing incidence of disease outbreaks is escalating demand for advanced diagnostic measures, which is expected to boost growth of the human immunoglobulin (pH4) for Intravenous Injection (COVID-19) market. For instance, the coronavirus disease (COVID-19) pandemic is the most recent outbreak which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO), around 1,991,562 cases of the coronavirus disease (COVID-19) were reported on April 16, 2020 across the globe.

Figure 2. Global Human Immunoglobulin (ph4) for Intravenous Injection (COVID-19) Market Value Share (%), by Disease Indication, 2020

Human Immunoglobulin (pH4) for Intravenous Injection  | Coherent Market Insights

The increasing approval of intravenous human immunoglobulin products is expected to drive the market growth during the forecast period

Approvals of intravenous human immunoglobulin products by regulatory authorities are expected to drive the growth of the human immunoglobulin (pH4) for intravenous injection (COVID-19) market during the forecast period. For instance, in September 2017, CSL Behring received the U.S. Food and Drug Administration (FDA) approval for Privigen, a human immune globulin intravenous liquid, indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.

Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Restraint

Side effects such as headache, cough, fatigue, infusion site reaction, nausea, urticaria, sinusitis, blood pressure increased, diarrhea, dizziness, and lethargy that are associated with human immunoglobulin (pH4) for intravenous injection are expected to hinder the market growth. For instance, on July 2017, Octapharma USA Inc. issued voluntary market withdrawal of one lot of Octagam, a human immune globulin intravenous liquid, as a result of increased hypersensitivity events such as urticaria, wheezing and anaphylactoid-type responses.

Key Players

Major players operating in the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc, China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.

Human immunoglobulin for intravenous injection (IVIG) has the capacity of proving passive immunity and anti-inflammatory, immunomodulatory effect which results in better treatment and prognosis of severe infections such as COVID-19. The IgG antibodies extracted from recovered patients of COVID- 19 are expected to boost the immune response in newly infected patients, leading to a reduction in the treatment duration. Hence, the combination of the immune IgG antibodies as human immunoglobulin for intravenous injection (IVIG) with antiviral drugs can offer short-term and medium-term solutions against COVID-19. Hence, the COVID-19 outbreak is expected to increase demand for human immunoglobulin (pH4) for intravenous injection which is expected to boost the growth of human immunoglobulin (pH4) for intravenous injection (COVID-19) market.

Market Dynamics

The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to enhance their market presence is expected to propel the market growth during the forecast period. For instance, in January 2020, ADMA Biologics, Inc., a manufacturer and distributor of plasma-derived biologics, entered a 5-year manufacturing and supply agreement with an undisclosed partner to produce and sell plasma-derived intermediate fractions from ADMA’s Immune Globulin (IG) manufacturing process. Under this agreement ADMA Biologics, Inc. will maximize the revenue per liter of plasma fractionated in its plant by selling the fractioned plasma to a third party to develop their own therapeutic products under their own licensed manufacturing processes.

Key features of the study:

  • This report provides in-depth analysis of the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc, China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, disease indication up-gradation, market expansion, and marketing tactics
  • The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market

Detailed Segmentation:

  • Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Type:
    • IgG
    • IgA
    • IgM
  • Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Disease Indication:
    • COVID-19
    • Primary Immunodeficiency Disease
    • Immune-mediated Thrombocytopenia
    • Kawasaki Disease
    • B Chronic lymphocytic Leukemia(B-CLL)
    • Others
  • Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Region:
    • North America
      • By Type
        • IgG
        • IgA
        • IgM
      • By Disease Indication:
        • COVID-19
        • Primary Immunodeficiency Disease
        • Immune-mediated Thrombocytopenia
        • Kawasaki Disease
        • B Chronic lymphocytic Leukemia(B-CLL)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Type
        • IgG
        • IgA
        • IgM
      • By Disease Indication:
        • COVID-19
        • Primary Immunodeficiency Disease
        • Immune-mediated Thrombocytopenia
        • Kawasaki Disease
        • B Chronic lymphocytic Leukemia(B-CLL)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type
        • IgG
        • IgA
        • IgM
      • By Disease Indication:
        • COVID-19
        • Primary Immunodeficiency Disease
        • Immune-mediated Thrombocytopenia
        • Kawasaki Disease
        • B Chronic lymphocytic Leukemia(B-CLL)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type
        • IgG
        • IgA
        • IgM
      • By Disease Indication:
        • COVID-19
        • Primary Immunodeficiency Disease
        • Immune-mediated Thrombocytopenia
        • Kawasaki Disease
        • B Chronic lymphocytic Leukemia(B-CLL)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type
        • IgG
        • IgA
        • IgM
      • By Disease Indication:
        • COVID-19
        • Primary Immunodeficiency Disease
        • Immune-mediated Thrombocytopenia
        • Kawasaki Disease
        • B Chronic lymphocytic Leukemia(B-CLL)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type
        • IgG
        • IgA
        • IgM
      • By Disease Indication:
        • COVID-19
        • Primary Immunodeficiency Disease
        • Immune-mediated Thrombocytopenia
        • Kawasaki Disease
        • B Chronic lymphocytic Leukemia(B-CLL)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Takeda Pharmaceutical Company Limited*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Baxter International Inc.
    • CSL Behring
    • Bayer AG
    • Grifols, S.A.
    • Octapharma AG
    • Shanghai RAAS Blood Products Co., Ltd.
    • Hualan Biological Engineering Inc.
    • China Biologic Products, Inc.
    • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
    • Boya Bio-Pharmaceutical Group Co., Ltd.
    • ADMA Biologics, Inc.
    • Sinopharm Group Co., Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Industry Trend
    • Merger and Acquisitions
    • New Disease Indication Approvals/Launch
    • Promotion and Marketing Initiatives
    • PEST Analysis
  4. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • IgG
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • IgA
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • IgM
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Disease Indication, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • COVID-19
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Primary Immunodeficiency Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Immune-mediated Thrombocytopenia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Kawasaki Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • B Chronic lymphocytic Leukemia(B-CLL)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Baxter International Inc.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CSL Behring
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Grifols, S.A.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Octapharma AG
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Shanghai RAAS Blood Products Co., Ltd.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hualan Biological Engineering Inc
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • China Biologic Products, Inc.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Boya Bio-Pharmaceutical Group Co., Ltd.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ADMA Biologics, Inc.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sinopharm Group Co., Ltd.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
        • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 27 market data tables and 26 figures on "Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market” - Global forecast to 2027.

Frequently Asked Questions

The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market size was valued at US$ 38,337.0 million in 2019.
The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market is estimated to exhibit a Compound Annual Growth Rate (CAGR) of 12.7% during the forecast period (2020-2027).
Major market drivers for human immunoglobulin (pH4) for intravenous injection (COVID-19) market include the increasing cases primary immunodeficiency disease and B Chronic lymphocytic Leukemia (B-CLL), disease outbreaks such as coronavirus (COVID 19), and approvals for extended use of human immunoglobulin (pH4) for intravenous injection from regulatory authorities.
IgG segment held major market share in 2019 owing to the increasing product approvals.
The North America human immunoglobulin (pH4) for intravenous injection (COVID-19) market is held highest revenue share in 2019.
The major players operating in the global human immunoglobulin (pH) for intravenous injection (COVID-19) market are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc., and others.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner